ALKemist Bio appoints Markus Dangl to Board of Directors as Chief Executive Officer

Turin, Italy, June 1, 2026 – ALKemist Bio, a biotechnology company dedicated to transforming the treatment of ALK-positive cancers, today announced the appointment of Dr. Markus Dangl to the company’s Board as Chief Executive Officer. Markus brings more than 25 years of experience in oncology and immunology drug development, including leading cell therapy programs at Achilles Therapeutics, where he helped close a £100M Series B as CSO, at Medigene, and at Evotec. He has successfully translated three cell-based assets into clinical development and has deep experience across autologous and allogeneic cell therapies and biologics-based immunotherapies, both in large pharma and early-stage biotech settings.

ALKemist is targeting ALK, one of oncology's most compelling targets. It is a cancer driver expressed across multiple solid and liquid tumors, absent in almost all healthy tissue, and backed by decades of clinical validation. Yet despite the success of ALK inhibitors, nearly all patients eventually relapse due to resistance mutations, leaving a large and growing unmet need that current therapies cannot address.

Markus joins ALKemist Bio at an important moment. Our lead program against ALK is in clinical phase 1/2 at Boston Children’s Hospital and Dana-Farber Cancer Institute, initially focused on pediatric solid tumors. Our two ALK-targeting TCR-T programs are advancing toward IND, with the frontrunner program expected to reach IND submission in early 2027, with NSCLC as primary indication. In addition, preclinical work on in vivo cell therapy programs will provide alternative development paths for the future.

The next chapter is building on this foundation and taking ALKemist through a Series A financing round to fund the clinical development of our pipeline and bring new treatment options to patients with ALK-positive cancers.